Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity

Autoimmunity Reviews

Volumn 12, Issue 3, 2013, Pages 430-435

  Visentini, Marcella ^a   Conti, Valentina ^a   Cristofoletti, Cristina ^b   Lazzeri, Cristina ^b   Marrapodi, Ramona ^a   Russo, Giandomenico ^b   Casato, Milvia ^a   Fiorilli, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Anergy; HCV; Marginal zone B cell; Mixed cryoglobulinemia; Splenic marginal zone lymphoma

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CD22 ANTIGEN; CD72 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; PEGINTERFERON; RHEUMATOID FACTOR; RIBAVIRIN; RITUXIMAB; STEROID; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR STRA13; UNCLASSIFIED DRUG; VH1 69 PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL THERAPY; APOPTOSIS; AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; CELL CLONE; CELL EXPANSION; CRYOGLOBULINEMIA; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MARGINAL ZONE B CELL; PHENOTYPE; PREVALENCE; REVIEW; TREATMENT RESPONSE; VIRUS REPLICATION; VIRUS STRAIN;

AUTOIMMUNITY; B-LYMPHOCYTES; CRYOGLOBULINEMIA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE ACTIVATION; RECEPTORS, COMPLEMENT 3D; SPLEEN;

EID: 84872425371     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.08.016     Document Type: Review

References (56)

1. Anonimous Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. J Viral Hepat 1999, 6:35-47.
2. Landau D.A., Saadoun D., Calabrese L.H., Cacoub P. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007, 6:581-587.
3. De Vita S., Soldano F., Isola M., Monti G., Gabrielli A., Tzioufas A., et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011, 70:1183-1190.
4. Pietrogrande M., De Vita S., Zignego A.L., Pioltelli P., Sansonno D., Sollima S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454.
5. Pons-Estel G.J., Salerni G.E., Serrano R.M., Gomez-Puerta J.A., Plasin M.A., Aldasoro E., et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 2011, 10:679-684.
6. Ferri C., Cacoub P., Mazzaro C., Roccatello D., Scaini P., Sebastiani M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11:48-55.
7. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F., Zaramella M., Monti M., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011, 10:714-719.
8. De Vita S., Quartuccio L., Isola M., Mazzaro C., Scaini P., Lenzi M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:843-853.
9. Sansonno L., Tucci F.A., Sansonno S., Lauletta G., Troiani L., Sansonno D. B cells and HCV: an infection model of autoimmunity. Autoimmun Rev 2009, 9:93-94.
10. Ramos-Casals M., De Vita S., Tzioufas A.G. Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev 2005, 4:8-15.
11. Palazzi C., Buskila D., D'Angelo S., D'Amico E., Olivieri I. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev 2012, 11:659-663.
12. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
13. Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005, 202:1171-1177.
14. Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007, 6:537-542.
15. Sousa G.M., Oliveira R.C., Pereira M.M., Paraná R., Sousa-Atta M.L., Atta A.M. Autoimmunity in hepatitis C virus carriers: involvement of ferritin and prolactin. Autoimmun Rev 2011, 10:210-213.
16. Dal Maso L., Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006, 15:2078-2085.
17. Saadoun D., Suarez F., Lefrere F., Valensi F., Mariette X., Aouba A., et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. Blood 2005, 105:74-76.
18. Matteucci C., Bracci M., Barba G., Carbonari M., Casato M., Visentini M., et al. Different genomic imbalances in low- and high-grade HCV-related lymphomas. Leukemia 2008, 22:219-222.
19. Casato M., Mecucci C., Agnello V., Fiorilli M., Knight G.B., Matteucci C., et al. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 2002, 99:2259-2261.
20. Hermine O., Lefrère F., Bronowicki J.P., Mariette X., Jondeau K., Eclache-Saudreau V., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89-94.
21. Suarez F., Lortholary O., Hermine O., Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006, 107:3034-3044.
22. Zignego A.L., Piluso A., Giannini C. HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. Autoimmun Rev 2008, 8:107-111.
23. Kasama Y., Sekiguchi S., Saito M., Tanaka K., Satoh M., Kuwahara K., et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010, 116:4926-4933.
24. Rosa D., Saletti G., De Gregorio E., Zorat F., Comar C., D'Oro U., et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 2005, 102:18544-18549.
25. De Vita S., Quartuccio L., Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimmun Rev 2008, 8:95-99.
26. Gragnani L., Piluso A., Giannini C., Caini P., Fognani E., Monti M., et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Arthritis Rheum 2011, 63:1446-1451.
27. Carbonari M., Caprini E., Tedesco T., Mazzetta F., Tocco V., Casato M., et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005, 174:6532-6539.
28. Charles E.D., Green R.M., Marukian S., Talal A.H., Lake-Bakaar G.V., Jacobson I.M., et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008, 111:1344-1356.
29. Perotti M., Ghidoli N., Altara R., Diotti R.A., Clementi N., De Marco D., et al. Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun Rev 2008, 7:468-472.
30. Ivanovski M., Silvestri F., Pozzato G., Anand S., Mazzaro C., Burrone O.R., et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998, 91:2433-2442.
31. Chan C.H., Hadlock K.G., Foung S.K., Levy S. The VH1-69 gene is preferentially used both by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001, 97:1023-1026.
32. Quinn E.R., Chan C.H., Hadlock K.G., Foung S.K., Flint M., Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001, 98:3745-3749.
33. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
34. Gorny M.K., Pan R., Williams C., Wang X.H., Volsky B., O'Neal T., et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 2012, 427:198-207.
35. Weller S., Braun M.C., Tan B.K., Rosenwald A., Cordier C., Conley M.E., et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004, 104:3647-3654.
36. Visentini M., Cagliuso M., Conti V., Carbonari M., Casato M., Fiorilli M. The V(H)1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21(low) phenotype. Blood 2011, 118:3440-3441.
37. Rakhmanov M., Keller B., Gutenberger S., Foerster C., Hoenig M., Driessen G., et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A 2009, 106:13451-13456.
38. Isnardi I., Ng Y.S., Menard L., Meyers G., Saadoun D., Srdanovic I., et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010, 115:5026-5036.
39. Moir S., Ho J., Malaspina A., Wang W., DiPoto A.C., O'Shea M.A., et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008, 205:1797-1805.
40. Baseggio L., Traverse-Glehen A., Callet-Bauchu E., Morel D., Magaud J.P., Berger F., et al. Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). Hematol Oncol 2011, 29:47-51.
41. Ehrhardt G.R., Hsu J.T., Gartland L., Leu C.M., Zhang S., Davis R.S., et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 2005, 202:783-791.
42. Ehrhardt G.R., Hijikata A., Kitamura H., Ohara O., Wang J.Y., Cooper M.D. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med 2008, 205:1807-1817.
43. Kardava L., Moir S., Wang W., Ho J., Buckner C.M., Posada J.G., et al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest 2011, 121:2614-2624.
44. Visentini M., Cagliuso M., Conti V., Carbonari M., Cibati M., Siciliano G., et al. Clonal B cells of HCV-associated mixed cryoglobulinemia patients contain exhausted marginal zone-like and CD21(low) cells overexpressing Stra13. Eur J Immunol 2012, 42:1468-1476.
45. Rubtsov A.V., Rubtsova K., Fischer A., Meehan R.T., Gillis J.Z., Kappler J.W., et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c[U+207A] B-cell population is important for the development of autoimmunity. Blood 2011, 118:1305-1315.
46. Hao Y., O'Neill P., Naradikian M.S., Scholz J.L., Cancro M.P. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 2011, 118:1294-1304.
47. Racine R., Chatterjee M., Winslow G.M. CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection. J Immunol 2008, 181:1375-1385.
48. Charles E.D., Brunetti C., Marukian S., Ritola K.D., Talal A.H., Marks K., et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011, 117:5425-5437.
49. Terrier B., Joly F., Vazquez T., Benech P., Rosenzwajg M., Carpentier W., et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 2011, 187:6550-6563.
50. Cambier J.C., Gauld S.B., Merrell K.T., Vilen B.J. B-cell anergy: from transgenic models to naturally occurring anergic B cells?. Nat Rev Immunol 2007, 7:633-643.
51. Kin N.W., Crawford D.M., Liu J., Behrens T.W., Kearney J.F. DNA microarray gene expression profile of marginal zone versus follicular B cells and idiotype positive marginal zone B cells before and after immunization with Streptococcus pneumoniae. J Immunol 2008, 180:6663-6674.
52. Martin F., Oliver A.M., Kearney J.F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 2001, 14:617-629.
53. Le Pottier L., Devauchelle V., Pers J.O., Jamin C., Youinou P. The mosaic of B-cell subsets (with special emphasis on primary Sjögren's syndrome). Autoimmun Rev 2007, 6:149-154.
54. Visentini M., Conti V., Cagliuso M., Siciliano G., Scagnolari C., Casato M., et al. Persistence of a large population of exhausted monoclonal B cells in mixed cryoglobuliemia after the eradication of hepatitis C virus infection. J Clin Immunol 2012, 32:729-735.
55. Peveling-Oberhag J., Crisman G., Schmidt A., Döring C., Lucioni M., Arcaini L., et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012, 26:1654-1662.
56. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109:4424-4431.